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Summary Carbogen and nicotinamide have been evaluated in a phase 11 study as hypoxia-modifying agents during radical radiotherapy for
bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a
dose of 80 mg kg-1 daily with 52.5 Gy in 20 fractions over 4 weeks, (b) carbogen alone, with 50 Gy in 20 fractions over 4 weeks, and (c)
carbogen and nicotinamide, with 50-52.5 Gy in 20 fractions over 4 weeks. Ten patients were treated in each group. All patients completed
carbogen and radiotherapy as prescribed, but only 45% completed daily nicotinamide over the 4-week treatment period. The end points of
this study were acute bowel and bladder morbidity and local control at cystoscopy 6 months after treatment. An expected level of acute bowel
and bladder morbidity was seen that reverted to normal in most patients by 12 weeks with no difference between the three treatment groups.
Complete response rates at 6 months were seven out of ten (100%) in the nicotinamide alone group, nine out of ten (90%) in the carbogen
alone group and seven out of ten (70%) in the carbogen and nicotinamide group. It is concluded that carbogen and nicotinamide may improve
the results of daily fractionated radiotherapy in bladder cancer and that further evaluation is required.
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Radical radiotherapy is an important treatment for the manage-
ment of muscle-invasive (T2, T3) and high-grade superficial
(TIG3) bladder cancer. It is not, however, universally effective,
and 5-year survival ranges from 30% to 50%, with local failure
being a major predictor of survival (Hope-Stone et al, 1981;
Duncan and Quilty, 1986). A dose-response relationship for
bladder carcinoma has been demonstrated using a hyperfraction-
ated schedule to 84 Gy, but even in this series, despite a 62%
complete remission rate at 6 months, the 5-year survival was only
37% (Edsmyr et al, 1985).
Possible mechanisms of radioresistance may include hypoxia,
repopulation andintrinsic radioresistance. The limited dataavailable
have shown thatbladdercancerhas a median potential cell-doubling
time of 17 days (Rew et al, 1991), which suggests that repopulation
is probably not a major feature in the failure of radiotherapy to
control bladder cancer. Intrinsic radioresistance might be expected
tobe modifiedby dose escalation, andthis has beendemonstrated in
the data quoted above. Despite dose escalation, however, a signifi-
cant failure rate was still seen, and 38% of patients failed ever to
achieve local control. This implies that hypoxia may also be impor-
tant in the control ofbladder cancer. Previous studies ofhyperbaric
oxygen andcarbogen havebeen unsuccessful inimproving response
rates relative to control arms without hypoxic modification, but
these studies can be criticized in terms of the dose fractionation
schedules employed (Cade et al, 1978) or the means of carbogen
administration (Keresteci and Rider, 1973).
In experimental models, there is evidence to support the use of
normobaric oxygen in the form of carbogen (95% oxygen, 5%
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carbon dioxide) as a hypoxic cell sensitizer (Rojas et al, 1990).
The change in tumourpO2 with carbogen is dependent upon the
duration of carbogen breathing. It has been shown in one study,
using the Eppendorf electrode to measure intratumoral pO2, that
this rises to a maximum within the first 10 min of carbogen
breathing, falling to baseline within 20 min (Falk et al, 1995). For
this reason early clinical trials using 1-2 h of prebreathing with
carbogen (Kestereci and Rider 1973; Rubin et al, 1979) cannot be
expected to have tested the potential value of carbogen as a
hypoxic modifier.
Nicotinamide is the amide of vitamin B3. Acute hypoxia within
tumours arises from intermittent closure ofblood vessels, resulting
in fluctuations in the tumour microcirculation (Chaplin et al, 1987;
Trotter et al, 1989). Nicotinamide overcomes acute hypoxia by
reducing these changes in the microcirculation (Kelleher and
Vaupel, 1993; Hill and Chaplin, 1995). Furthermore, when nicotin-
amide is combined with carbogen, additional tumour sensitivity to
radiation has been demonstrated, with overall enhancement ratios
of between 1.8 and 2.1 in animal models using clinically relevant
dose schedules of 2 Gy day-' (Kjellen et al, 1991; Rojas et al,
1993). It has therefore been proposed that the combination of
carbogen and nicotinamide provides the optimal means of over-
coming tumour hypoxia. When combined with acceleration of the
radiation schedule, this treatment has been termed ARCON (accel-
erated radiotherapy carbogen and nicotinamide) (Rojas, 1992). The
feasibility of ARCON treatment for carcinoma of the bladder has
been evaluated in a formal phase II programme.
PATIENTS AND METHOD
Between January 1994 and the present time, sequential patients
referred for radical radiotherapy for bladder carcinoma have been
entered into a phase II study evaluating nicotinamide as a single
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Table 1 Patient details
Nicotinamide Carbogen NIC/CARB
(52.5 Gy/20 fractions) (50 Gy/20 fractions) (50-52.5 Gy/20 fractions)
Number 10 10 10
Age (median) 66 69 69
Male/female 9:1 10:0 8:2
Stage
Ti 1 1 1
T2 3 2 2
T3 6 7 7
Table 2 Urinary frequency. Number of patients with urinary frequency hourly
or more
Nicotinamide Carbogen NIC/CARB
Time from day 1
radiotherapy weeks
4 6 5 5
12 2 2 1
Table 3 Bowel function. Bowel motions per day (24 h): median (range)
Nicotinamide Carbogen NIC/CARB
Time from day 1
radiotherapy (weeks)
4 4 (1-6) 3 (1-6) 2.5 (2-14)
12 1 (1-4) 2 (1-5) 1 (1-3)
Table 4 Local control at cystoscopy 6 months after radiotherapy
Nicotinamide Carbogen NIC/CARB
Intercurrent death
From bladder cancer 1 0 2
Other cause 0 1 0
Lost to follow-up 0 0 1
Assessable 9 9 7
Complete remission 7 9 7
Per cent response by intention to treat 70 90 70
agent, carbogen as a single agent and the combination of nicotin-
amide and carbogen. This report includes the first 30 of these
patients. Patients were selected for radical radiotherapy by virtue
of having high-grade superficial bladder carcinoma (T1G3) or
muscle-invasive bladder carcinoma (T2, T3a or T3b). All patients
had pretreatment staging, computerized tomography (CT) scan
and chest radiograph together with routine blood tests, including
liver function tests. Only patients with no evidence of disease
beyond the bladder or perivesical tissues were entered into the
protocol for radical radiotherapy.
Three sequential cohorts of patients received treatment. The
first ten patients received nicotinamide alone at a dose of
80 mg kg-'. The second group of ten patients received carbogen
and the third group of patients both nicotinamide and carbogen.
Demographic details including age, sex and tumour stage are
shown in Table 1.
Radiation planning anddelivery was standard in all patients. The
tumourvolume was definedusing CTplanning to coverthe bladder
with a 2-cm margin. Patients were planned and treated with the
bladder empty and a three-field plan was produced with 6- or 15-
MV photons. The treatment prescription forthe nicotinamide group
was 52.5 Gy minimum tumour dose in 20 daily fractions over 4
weeks. The dose was reduced in the carbogen alone group to 50 Gy
in 20 daily fractions over4 weeks because ofthe concern regarding
possible bowel sensitization with carbogen, based on experience
with hyperbaric oxygen (Dische 1991). The first five ARCON
patients also received the lower dose of 50 Gy, which was
increased to 52.5 Gy for the remaining five patients. Plans were
produced to cover the target volume with the 90% isodose using
normalization to the ICRU maximum isodose (100%).
Nicotinamide was administered at a dose of 80 mg kg-' on the
basis of our previous pharmocokinetic work and administered
orally 1.5 h before the time of radiation delivery (Hoskin et al,
1995; Stratford et al, 1996). Rapid-release nicotinamide tablets
500 mg and 1 g (Larkhall) were used for all patients. Random peak
blood levels were measured by high-performance liquid chro-
matography (HPLC) to assess compliance. Patients were seen
weekly during treatment and thereafter until resolution of acute
toxicity, when they were seen monthly until 6 months after treat-
ment at the time oftheir check cystoscopy. At each visit, details of
bowel and urinary function were scored according to the Dische
scoring system (Dische et al, 1989).
Carbogen was delivered through a closed breathing system
using a face mask (Laerdal Medical Systems) and one-way valve
at a flow rate of 15 1 min-.1 Carbogen breathing was started 5 min
before radiation delivery during the set-up of the patient and
continued throughout the radiation delivery.
RESULTS
Urine function was recorded in terms of urine frequency. Table 2
demonstrates the number of patients with urinary frequency of
more than once per hour and it can be seen that in most patients
there is a return to less frequent urine function by 12 weeks after
treatment. A similar effect of treatment upon frequency of bowel
motion is shown in Table 3. Data for late toxicity are as yet not
available, but in those patients followed for more than 1 year no
late bowel morbidity has emerged. One patient has required a
persisting indwelling catheter because of a fibrosed bladder.
The results for local control as measured by response at
cystoscopy 6 months after radiotherapy are shown in Table 4. All
patients but one in each of the two carbogen cohorts completed
carbogen breathing uneventfully. In contrast, however, only 45%
of patients completed nicotinamide as prescribed. Details of
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Table 5 Nicotinamide compliance. Number continuing to take nicotinamide
Day 1 Day8 Day 15 Day22 Day26
Full dose 20 12 11 10 9
Reduced dose 0 3 3 3 3
Total 20 15 14 13 12
Per cent compliance 100 60 55 50 45
(80 mg kg-1)
Per cent compliance
(any dose) 100 75 70 65 60
Table 6 Response related to nicotinamide compliance
Nicotinamide dose
Full dose Reduced dose Discontinued
Number of patients
(number having carbogen) 9 (6) 3 (1) 8 (3)
Complete response at 6 months
(number having carbogen) 8 (5) 2 (1) 4 (1)
Per cent response 89 67 50
nicotinamide compliance are shown in Table 5. The principal
reason for nicotinamide intolerance was persistent nausea
leading to vomiting despite the administration of regular anti-
emetics, including dexamethasone, cyclizine, metoclopromide or
ondansetron. The effect of nicotinamide compliance on tumour
control is shown in Table 6. Plasma levels of nicotinamide were
measured in 14 patients: five due to receive nicotinamide alone
and nine in the ARCON group. The results for plasma nicoti-
namide levels taken at 1 h after oral administration, approximately
30 min before radiotherapy, are shown in Table 7. In two patients
non-compliance, otherwise unsuspected, was detected from the
plasma levels.
DISCUSSION
This phase II study has demonstrated that the administration of
carbogen with a 4-week radical radiotherapy schedule in the treat-
ment of bladder cancer is feasible. No excess bowel or bladder
morbidity has been observed and very high rates of local control
are recorded at 6 months. Similar local control rates are seen in all
three groups receiving either nicotinamide alone, carbogen alone
or the combination ofnicotinamide and carbogen.
The administration of nicotinamide on a daily basis over 4
weeks with radical radiotherapy has been troublesome. Around
half of patients have not tolerated the medication and have felt
unable to continue with it. This occurs at differing times through
the 4-week schedule, with no clear pattern emerging, although
most patients having early problems discontinue nicotinamide
within the first week. The nausea experienced is a particularly
intractable symptom that, unlike chemotherapy or radiotherapy-
induced nausea and vomiting, does not seem to respond well to
conventional antiemetic drugs. These observations are consistent
with those noted in our previous volunteer and patient phase I
studies (Stratford et al, 1996) and our experience in patients with
head and neck cancer receiving ARCON (Saunders et al, 1996).
The impact of nicotinamide on tumour control assays in animal
models varies according to the tumour type. In the mouse
mammary carcinoma CaNT, tumour nicotinamide increases the
enhancement ratio with carbogen alone from 1.5 to 1.7 during
conventional fractionation (Rojas et al, 1996), but in the KHT
sarcoma model an effect as great as carbogen alone is seen with
nicotinamide alone, each achieving an enhancement ratio of 1.9
(Siemann et al, 1994), with no increase when the two are
combined. Analysis ofthose patients who completed nicotinamide
compared with those who did not, as shown in Table 6, suggests
that nicotinamide compliance may predict for a better outcome,
although interpretation of such small subgroups can at best only
show a trend.
The radiation schedule used in this pilot study is one that
implies modest acceleration compared with the conventional 6-6.5
week schedule delivering 60-65 Gy. It is, however, one that has
been used at both this institution and other major centres, which
report 6-month local control rates of between 45% and 58%. The
overall figure of77% (23 out of30) noted in this series is therefore
encouraging but must be interpreted with caution in view of the
small numbers involved. Nonetheless, in the absence of excess
morbidity, these data make a strong argument for pursuing
carbogen as delivered here in a phase III randomized trial. Despite
the poor compliance, patients receiving nicotinamide alone also
had a high rate of response, with 70% in complete remission at
Table 7 Plasma nicotinamide levels in samples taken one hour after oral administration of 80 mg kg-' nicotinamide
Patient Nicotinamide-only group ARCON group
(concentration, nmol ml-') Day of samplinga (concentration, nmol ml-') Day of samplinga
1 719 7 Ob 7
2 1054 15 1194 7
3 1013 7 1416 8
4 Ob 15 1247 7
5 1368 5 1615 7
6 - 1578 7
7 _ 1698 7
8 - 1722 8
9 - 1813 7
10
aTime from day 1 of radiotherapy; bReflects non-compliance despite claims of patient; -, plasma sample not collected.
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6 months, and the data shown in Table 6 imply that those taking
nicotinamide may have a better outcome than those who discon-
tinue the drug. It has recently been shown that nicotinamide toxi-
city relates to plasma levels and that in patients who experience
moderate to severe toxicity associated with high plasma nicotin-
amide levels a dose reduction from the 80 mg kg-' used in this
study, to 60 mg kg-' enables continued administration of
nicotinamide while still achieving the threshold concentration for
radiosensitization of 700 nmol ml-' (Kaanders et al, 1997). The
approach using dose titration against toxicity is currently under
formal evaluation in bladder cancer patients receiving ARCON
with a 4-week radiation schedule.
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